| Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy | |
| Kusumoto, Shigeru; Arcaini, Luca; Hong, Xiaonan; Jin, Jie; Kim, Won Seog; Kwong, Yok Lam; Peters, Marion G.; Tanaka, Yasuhito; Zelenetz, Andrew D.; Kuriki, Hiroshi | |
| 刊名 | BLOOD
 |
| 2019 | |
| 卷号 | 133期号:2 |
| ISSN号 | 0006-4971 |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3596136 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Kusumoto, Shigeru,Arcaini, Luca,Hong, Xiaonan,et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy[J]. BLOOD,2019,133(2). |
| APA | Kusumoto, Shigeru.,Arcaini, Luca.,Hong, Xiaonan.,Jin, Jie.,Kim, Won Seog.,...&Tobinai, Kensei.(2019).Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.BLOOD,133(2). |
| MLA | Kusumoto, Shigeru,et al."Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy".BLOOD 133.2(2019). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论